IPSC

Century Therapeutics Inc

Add to Watchlist

Advanced Chart

0.626

-0.034(-5.154%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.6699

Open

0.6615

VWAP

0.63

Vol

1.20M

Mkt Cap

53.90M

Low

0.614

Amount

758.43K

EV/EBITDA(TTM)

Total Shares

84.50M

-111.22M

EV/OCF(TTM)

P/S(TTM)

0.46

Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

0.00

-100%

0.00

-100%

0.00

-100%

Estimates Revision

The market is revising Upward the revenue expectations for Century Therapeutics, Inc. (IPSC) for FY2025, with the revenue forecasts being adjusted by 61.13% over the past three months. During the same period, the stock price has changed by 25.72%.

Revenue Estimates for FY2025

Revise Upward

+61.13%

In Past 3 Month

Stock Price

Go Up

+25.72%

In Past 3 Month

5 Analyst Rating

539.39% Upside

Wall Street analysts forecast IPSC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IPSC is 4.00 USD with a low forecast of 2.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

1 Hold

0 Sell

Strong Buy

539.39% Upside

Current: 0.626

Low

2.00

Averages

4.00

High

7.00

539.39% Upside

Current: 0.626

Low

2.00

Averages

4.00

High

7.00

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Maintains

$5 → $2

2025-04-03

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$5 → $2

2025-04-03

Maintains

Strong Buy

Reason

Guggenheim

Kelsey Goodwin

Strong Buy

Reiterates

n/a

2025-03-28

Reason

Guggenheim

Kelsey Goodwin

Price Target

n/a

2025-03-28

Reiterates

Strong Buy

Reason

Guggenheim analyst Kelsey Goodwin lowered the firm's price target on Century Therapeutics to $5 from $12 and keeps a Buy rating on the shares. Century Therapeutics reported FY24 results and a business update that included a pre-planned pipeline re-prioritization, and announced the discontinuation of CNTY-101 in relapsed and refractory non-Hodgkin lymphoma in the ELiPSE-1 trial, which was largely expected by the Street, the analyst tells investors in a research note. The firm views Century as a differentiated player in the large autoimmune space in the near-term, and a leader in the field of induced pluripotent stem cell-derived cell therapies longer term.

Chardan Capital

Geulah Livshits

Strong Buy

Maintains

$11 → $7

2025-03-24

Reason

Chardan Capital

Geulah Livshits

Price Target

$11 → $7

2025-03-24

Maintains

Strong Buy

Reason

Chardan lowered the firm's price target on Century Therapeutics to $7 from $11 and keeps a Buy rating on the shares. The company reported Q4 results and announced a pipeline re-prioritization, including discontinuation of the Phase I ELiPSE-1 trial evaluating the company's lead CD19 CAR-iNK candidate CNTY-01 in late-stage non-Hodgkin's lymphoma, the analyst tells investors in a research note. The firm cut the price target to reflect the pipeline prioritization.

Guggenheim

Kelsey Goodwin

Strong Buy

Maintains

$12 → $5

2025-03-21

Reason

Guggenheim

Kelsey Goodwin

Price Target

$12 → $5

2025-03-21

Maintains

Strong Buy

Reason

Piper Sandler

Edward Tenthoff

Buy

Maintains

$4 → $2

2025-03-20

Reason

Piper Sandler

Edward Tenthoff

Price Target

$4 → $2

2025-03-20

Maintains

Buy

Reason

Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Century Therapeutics to $2 from $4 and keeps an Overweight rating on the shares. Century will dose the first autoimmune disease patient in the Phase I CALiPSO-1 study of CD19 CAR-iNK CNTY-101 this month with initial data in 2025, the firm notes. Piper also highlights that Century discontinued the Phase I ELiPSE-1 study in r/rNHL to focus resources on autoimmune disease.

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

2025-01-22

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

2025-01-22

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Century Therapeutics Inc (IPSC.O) is -0.41, compared to its 5-year average forward P/E of -3.67. For a more detailed relative valuation and DCF analysis to assess Century Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.67

Current PE

-0.41

Overvalued PE

0.61

Undervalued PE

-7.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.09

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

2.14

Undervalued EV/EBITDA

-6.32

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

55.54

Current PS

0.00

Overvalued PS

91.17

Undervalued PS

19.91